Pyrimidine and triazine compound preparation method and application

A kind of compound, the technology of hydrate, applied in the new pyrimidine and triazine compound, the pharmaceutical composition containing the compound, the preparation treatment and/or the medicine field of preventing cancer and other proliferative diseases

Inactive Publication Date: 2012-09-12
SHENYANG PHARMA UNIVERSITY
View PDF2 Cites 49 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Abnormal regulation mechanism of mTOR can lead to abnormal proliferation and differentiation of tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimidine and triazine compound preparation method and application
  • Pyrimidine and triazine compound preparation method and application
  • Pyrimidine and triazine compound preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0188] Embodiment 1: ( E )-4,4'-[6-[2-[1-(3-chlorobenzyl)-1 H -Indol-3-yl]methylidenehydrazino]-[1,3,5]-triazine-2,4-diyl]dimorpholine

[0189] ESI-MS [M+H] (m / z):534 ; m.p.129-130℃; 1 H NMR (300 MHz, DMSO) δ 10.59 (s, 1H), 8.46 (d, J = 7.7 Hz, 1H), 8.27 (s, 1H), 7.87 (s, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.34 (m, 3H), 7.16 (m, 3H), 5.45 (s, 2H), 3.73 (s, 8H), 3.64 (s, 8H).

Embodiment 2

[0190] Embodiment 2: ( E )-4,4'-[6-[2-[1-(4-methylbenzyl)-1 H -Indol-3-yl]methylidenehydrazino]-[1,3,5]-triazine-2,4-diyl]dimorpholine

[0191] ESI-MS [M+H] (m / z): 513.26 m.p.:137-139℃; 1H NMR (300 MHz, DMSO) δ 10.58 (s, 1H), 8.45 (d, J = 7.4 Hz, 1H), 8.26 (s, 1H), 7.84 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.3 Hz, 2H), 7.32-7.02 (m, 4H), 5.43 (s, 2H), 3.73 (s, 8H), 3.64 (s, 8H), 1.06 (s, 3H).

Embodiment 3

[0192] Embodiment 3: ( E )-4,4'-[6-[2-[1-(3,4-dichlorobenzyl)-1 H -Indol-3-yl]methylidenehydrazino]-[1,3,5]-triazine-2,4-diyl]dimorpholine

[0193] ESI-MS [M+H] (m / z): 567.17; m.p. 135-137℃; 1 H NMR (300 MHz, DMSO) δ 10.60 (s, 1H), 8.47 (d, J = 7.7 Hz, 1H), 8.27 (s, 1H), 7.87 (s, 1H), 7.56 (dd, J = 9.4, 5.0 Hz, 2H), 7.49 (d, J = 8.1 Hz, 1H), 7.30-7.04 (m, 3H), 5.45 (s, 2H), 3.74 (s, 8H), 3.65 (s, 8H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to pyrimidine and triazine compounds represented as a general formula I, geometric isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, wherein substituents R1, R2, R3 and X have the meanings defined in the description. The invention further relates to uses of the compounds represented as the general formula I in preparing medicine for treating and / or preventing cancer and other hyperplasia diseases.

Description

technical field [0001] The present invention relates to novel pyrimidine and triazine compounds, their geometric isomers and their pharmaceutically acceptable salts, hydrates, solvates or prodrugs, their preparation methods and pharmaceutical compositions containing the compounds. The present invention also relates to the use of pyrimidine and triazine compounds in the preparation of medicines for treating and / or preventing cancer and other proliferative diseases. Background technique [0002] Malignant tumor is a disease that seriously endangers human life and health. With the change of external factors such as environmental pollution, the number of cancer cases in the world is increasing year by year. According to the statistics of the World Health Organization (WHO), about 10 million people are diagnosed every year in the world. Cancer patients, 7 million people died of related diseases caused by tumors, so malignant tumors have become the second major killer of human bei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D403/12A61K31/5377A61K31/506A61K31/53A61P35/00
Inventor 宫平赵燕芳刘亚婧翟鑫朱五福
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products